BMS-599626

DB12318InvestigationalSmall molecule

BMS-599626 has been used in trials studying the treatment of Cancer, Metastases, and HER2 or EGFR Expressing Advanced Solid Malignancies.

Mechanism: Pharmacologically active on Receptor tyrosine-protein kinase erbB-2, Receptor tyrosine-protein kinase erbB-4, and Epidermal growth factor receptor
Curator reviewed
Formula / weight: C₂₇H₂₇FN₈O₃ · 530.564 g/mol (avg)
Code names: AC-480

Resolves to

Compound

Structure

InChIKeyLUJZZYWHBDHDQX-QFIPXVFZSA-NSMILESCC1=C2N(C=C1NC(=O)OC[C@@H]1COCCN1)N=CN=C2NC1=CC=C2N(CC3=CC=CC(F)=C3)N=CC2=C1

Targets

What you can answer from here — as of June 15, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

11+ReferencesStructured and connected to the statements they support

Which drugs share a target with BMS-599626, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.